Holen Sie sich die Stockscreener-App
114.64
0.61%
0.695
Handel nachbörslich:
114.64
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$113.94
Offen:
$112.06
24-Stunden-Volumen:
331.08K
Relative Volume:
2.87
Marktkapitalisierung:
$2.17B
Einnahmen:
$152.42M
Nettoeinkommen (Verlust:
$45.24M
KGV:
79.61
EPS:
1.44
Netto-Cashflow:
$6.97M
1W Leistung:
-1.94%
1M Leistung:
+2.76%
6M Leistung:
+43.64%
1J Leistung:
+65.35%
1-Tages-Spanne:
$111.00
$115.47
1-Wochen-Bereich:
$111.00
$124.03
52-Wochen-Spanne:
$67.53
$129.90
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Firmenname
Ligand Pharmaceuticals Inc
Sektor
Branche
Telefon
858-550-7500
Adresse
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Vergleichen Sie LGND mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
114.64 | 2.17B | 152.42M | 45.24M | 6.97M | 2.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-03 | Eingeleitet | Oppenheimer | Outperform |
| 2024-07-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-04-14 | Fortgesetzt | Stephens | Overweight |
| 2021-02-04 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-06 | Eingeleitet | Barclays | Overweight |
| 2020-03-24 | Herabstufung | Argus | Buy → Hold |
| 2020-03-10 | Eingeleitet | Guggenheim | Neutral |
| 2020-02-06 | Eingeleitet | The Benchmark Company | Buy |
| 2019-09-19 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-06-11 | Eingeleitet | Barclays | Equal Weight |
| 2019-05-03 | Bestätigt | H.C. Wainwright | Buy |
| 2019-03-06 | Bestätigt | H.C. Wainwright | Buy |
| 2018-10-29 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2018-10-02 | Bestätigt | H.C. Wainwright | Buy |
| 2018-09-11 | Bestätigt | Argus | Buy |
| 2018-08-17 | Eingeleitet | Goldman | Neutral |
| 2018-08-08 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2018-06-21 | Eingeleitet | Argus | Buy |
| 2017-12-27 | Bestätigt | H.C. Wainwright | Buy |
| 2017-09-05 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-10-05 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-05 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2016-03-11 | Eingeleitet | Sidoti | Buy |
| 2016-03-03 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Ligand Pharmaceuticals Inc Aktie (LGND) Neueste Nachrichten
Wellington Management Group LLP Trims Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
What is Zacks Small Cap's Forecast for LGND FY2025 Earnings? - MarketBeat
Zacks Small Cap Has Strong Estimate for LGND FY2026 Earnings - MarketBeat
Fmr LLC Raises Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Ligand Pharmaceuticals: A Strong Growth Trajectory with Impressive Returns and Strategic Advancements - mediahousepress
LGND: 2025 View Calls for 17% Topline Growth - Zacks Small Cap Research
Ligand Pharmaceuticals' SWOT analysis: diversified royalty model drives stock growth - Investing.com Australia
Barclays Boosts Ligand Pharmaceuticals (NASDAQ:LGND) Price Target to $160.00 - MarketBeat
Ligand Pharmaceuticals' SWOT analysis: stock poised for growth amid challenges By Investing.com - Investing.com South Africa
Ligand Pharmaceuticals' SWOT analysis: stock poised for growth amid challenges - Investing.com India
Ligand Pharmaceuticals' SWOT analysis: royalty aggregator stock poised for growth - Investing.com
What is HC Wainwright's Estimate for LGND FY2025 Earnings? - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 6,031 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Ligand price target raised to $151 from $135 at Oppenheimer - Yahoo Finance
Demystifying Ligand Pharmaceuticals: Insights From 10 Analyst Reviews - Benzinga
Ligand Pharmaceuticals' (LGND) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Ligand forecasts revenue growth and higher earnings for 2025 By Investing.com - Investing.com Canada
Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance - BioSpace
5,961 Shares in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Purchased by Verition Fund Management LLC - MarketBeat
Ligand forecasts revenue growth and higher earnings for 2025 - Investing.com
Ligand Pharmaceuticals Investor And Analyst Day At 10:30 AM ET - Nasdaq
Ashford Capital Management Inc. Sells 11,800 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Charles Schwab Investment Management Inc. Has $16.41 Million Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Erste Asset Management GmbH Purchases Shares of 4,300 Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Ligand Pharmaceuticals Insiders Sell US$6.3m Of Stock, Possibly Signalling Caution - Simply Wall St
RBC upgrades Ligand Pharma shares target ahead of guidance report By Investing.com - Investing.com Canada
RBC upgrades Ligand Pharma shares target ahead of guidance report - Investing.com
John L LaMattina At Ligand Pharmaceuticals Executes Options Exercise, Realizing $169K - Benzinga
Ligand Pharmaceuticals director John LaMattina sells $297,501 in stock By Investing.com - Investing.com Nigeria
Ligand Pharmaceuticals director John LaMattina sells $297,501 in stock - Investing.com
LGND (Ligand Pharmaceuticals) Shares Outstanding (EOP) : 18.8 Mil (As of Sep. 2024) - GuruFocus.com
34,069 Shares in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Bought by Edgestream Partners L.P. - MarketBeat
Isthmus Partners LLC Sells 9,622 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Fisher Asset Management LLC Purchases 6,555 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Loomis Sayles & Co. L P Buys 114,436 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Bought by Victory Capital Management Inc. - MarketBeat
Ligand Pharmaceuticals (FRA:LGDN) Inventories, Finished Goo - GuruFocus.com
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Acquired by Connor Clark & Lunn Investment Management Ltd. - MarketBeat
Analysts Set Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Target Price at $144.83 - MarketBeat
Ligand Pharmaceuticals' SWOT analysis: stock's growth potential in focus - Investing.com India
Royce & Associates LP Has $610,000 Stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Ligand Pharmaceuticals (STU:LGDN) Future 3-5Y EPS without N - GuruFocus.com
Ligand Pharmaceuticals (NASDAQ:LGND) Shareholders Should Be Cautious Despite Solid Earnings - Yahoo Finance
Janus Henderson Group PLC Expands Stake in Ligand Pharmaceuticals Inc - GuruFocus.com
Ligand Pharmaceuticals to Present at Stifel 2024 Healthcare Conference | LGND Stock News - StockTitan
Royal Bank of Canada Forecasts Strong Price Appreciation for Ligand Pharmaceuticals (NASDAQ:LGND) Stock - MarketBeat
Ligand Pharmaceuticals (NASDAQ:LGND) Given New $150.00 Price Target at Barclays - Defense World
Finanzdaten der Ligand Pharmaceuticals Inc-Aktie (LGND)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ligand Pharmaceuticals Inc-Aktie (LGND) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| LAMATTINA JOHN L | Director |
Nov 27 '24 |
Sale |
123.65 |
2,406 |
297,502 |
29,515 |
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):